Middle-East and Africa Dermatology Drug Market are expected to grow at a CAGR of 7% during 2021-2026

The growth of the Middle-East and Africa Dermatology Drug Market attributed to an increase in the occurrence of skin diseases and a rise in awareness regarding treatment and diagnostic of skin-related problems such as acne, dermal ulcer, alopecia, etc. Moreover, burgeoning R&D activities to develop a diverse product portfolio in dermatology drugs and the snowballing number of mergers & acquisitions would provide the opportunity for the lucrative growth of the market in the forthcoming timeline.

Get a sample copy of the report: https://www.marknteladvisors.com/research-library/middle-east-africa-dermatology-drugs-market.html

Key questions answered in the study
1. What are the current and future trends in Middle-East and Africa Dermatology Drug Market?
2. How the market has been evolving in terms of end-user demand and application areas?
3. How the competition has been shaping across the countries followed by their comparative factorial indexing?
4. What are the key growth drivers and challenges for Middle-East and Africa Dermatology Drug Market?
5. What are the customer orientation, purchase behaviour, and expectations from the Middle-East and Africa Dermatology Drug Market service provider across various Countries?

Acne Segment showed substantial growth
According to the MarkNtel Advisors’ research report, “Middle-East and Africa Dermatology Drug Market Analysis, 2021”. the Middle-East and Africa Dermatology Drug Market is anticipated to grow at a CAGR of around 7% during 2021-26. Based on Application, the Acne segment is anticipated to grow at a considerable rate in the forecasted period due to the high demand for acne-related dermatology drugs as a majority of the population between the age of 12-24 suffers at least minor acne problems. Further, the prevalence of acne is also increasing among the adult population due to various reasons such as climatic change, increase in stress level and bacteria build-up. This further contributes to a growth opportunity for the growth of the dermatology drug market.

“Middle-East and Africa Dermatology Drug Market Analysis, 2021” provides comprehensive qualitative and quantitative insights on the market potential, key factors impacting the market growth, hotspots and opportunities available for dermatology drug providers across the country. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitor's capabilities on 16 parameters. This will help companies in the formulation of Go to Market Strategies and identifying the blue ocean for its offerings.

For detailed analysis, visit: https://www.marknteladvisors.com/research-library/middle-east-africa-dermatology-drugs-market.html

Prescription based drugs dominate the market
Based on Prescription Mode, the market is bifurcated into prescription-based drugs and OTC drugs. Among these, prescription-based drugs have acquired the largest share in the Middle-East and Africa Dermatology Drug Market during the forecasted period. This is due to mounting awareness regarding skin diseases and a rise in the number of people consulting dermatologists for chronic skin problems. Moreover, an increase in the number of dermatological clinics increases the availability of a wide range of prescription-based dermatology drugs propels the growth of the market as revealed by MarkNtel Advisors’ research report “Middle-East and Africa Dermatology Drug Market Analysis, 2021”.

According to MarkNtel Advisors, the major leading players in the GCC Facility Management market are Bausch Health Companies Inc., Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co. Inc., Amgen Inc., AbbVie Inc., Eli Lilly and Company, Galderma S.A., GlaxoSmithKline plc, Mylan N.V.

Market Segmentation:
1. By Drug Type (Branded, Generics)
2. By Drug Class (Corticosteroids, Retinoid, Monoclonal Antibodies, Antibiotics Agents, Antiviral Agents, Antifungal Drugs, Antihistamines Agents, Immunosuppressive Drugs)
3. By Application (Psoriasis, Atopic dermatitis, Acne, Rosacea, Skin cancer, Scar, Others)
4. By End Users (Hospitals, Cosmetic-Centers, Dermatology Clinics, Homecare, Others)
5. By Prescription Mode (Prescription Based Drugs, OTC Drugs)
6. By Route of Administration (Topical, Oral, Parenteral)
7. By Distribution Channel (Direct, Retail/wholesale, Online)
8. By Geographic Region (UAE, Saudi Arabia, Qatar, Turkey, South Africa)
9. By Competitors (Bausch Health Companies Inc., Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co. Inc., Amgen Inc., AbbVie Inc., Eli Lilly and Company, Galderma S.A., GlaxoSmithKline plc, Mylan N.V.)

MarkNtel Advisors
1147 88AVE, Delta, British Columbia, BC,V4C,3B8, CANADA
Email: sales@marknteladvisors.com
Tel: +1613-707-5086
Website: https://www.marknteladvisors.com

MarkNtel Advisors is a leading research, consulting and data analytics firm that provides a wide range of strategic reports on diverse industry verticals to a substantial and varied client base that includes multinational corporations, financial institutions, governments, and individuals.

We specialize in niche industries and emerging geographies to support our clients in the formulation of strategies viz. Go to Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, trend analysis, etc. in around 15 industry verticals to enable our clients in identifying attractive investment opportunities and maximizing ROI through an early mover advantage.

This release was published on openPR.